DNA damage repair inhibitors for treatment of cancer
US8143241B2 · kind B2 · utility
12Cited by
10References
19Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Oct 6, 2005 |
| Grant date | Mar 27, 2012 |
| Priority date | — |
| Expiry date | Nov 17, 2028 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to the recognition that inhibition of the base excision repair pathway is selectively lethal in cells which are deficient in HR dependent DNA DSB repair. Methods and means relating to the treatment of cancers which are deficient in HR dependent DNA DSB repair using inhibitors which target base excision repair components, such as PARP, is provided herein.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.